<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059772</url>
  </required_header>
  <id_info>
    <org_study_id>ReCaLL-2013</org_study_id>
    <nct_id>NCT02059772</nct_id>
  </id_info>
  <brief_title>Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema</brief_title>
  <acronym>ReCaLL</acronym>
  <official_title>Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate if a combination therapy with micropulse
      diode laser treatment shows non inferiority on visual acuity within 12 months in comparison
      to standard therapy (intravitreal injection of ranibizumab only).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 30, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in best corrected visual acuity (BCVA)</measure>
    <time_frame>baseline, 12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in central macular thickness</measure>
    <time_frame>baseline, 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of intravitreal Lucentis injections</measure>
    <time_frame>within 12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy of diabetic macular edema with Lucentis (ranibizumab) according to SmPC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of standard therapy of Lucentis (ranibizumab) according to SmPC and micropulse diode laser treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>micropulse diode laser</intervention_name>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-ischemic diabetic macular edema with resulting reduction in visual
             functionality by determination of best corrected visual acuity (BCVA), ophthalmologic
             investigation, SD-OCT, FAG and anamnesis

          -  BCVA between 0.05 and 0.6 or retinal thickness &gt; 300 µm determined by SD-OCT

          -  The informed consent form must be signed before any study specific tests or procedures
             are done

          -  Confirmation of the subject's health insurance coverage prior to the first screening
             visit

          -  Age at least 18 years (inclusive) at the first screening visit

          -  Ability to understand and follow study-related instructions

        Exclusion Criteria:

          -  Severe ischemic maculopathy of the study eye

          -  Active neovascularization of iris or retina in the study eye

          -  History of intravitreal injection of VEGF-inhibitor or steroids in study eye within
             the last 3 month

          -  Pathologies of the anterior segment of the study eye with reduced visual acuity (e.g.
             corneal opacification, advanced cataract)

          -  Advanced glaucoma with central defects of the visual field in study eye

          -  Retinal pathologies with reduced visus (e.g. central scars, age related macular
             degeneration) in study eye

          -  Retinal vascular occlusion in medical history of study eye

          -  Active or suspected ocular or periocular infections

          -  Active intraocular inflammation in study eye

          -  Intraocular surgery of study eye within the last 6 months

          -  Laser therapy of study eye within the last 6 months

          -  Systemic steroid therapy within the last 3 month

          -  HbA1c &gt;10%

          -  Systolic blood pressure above 170 mmHg and diastolic blood pressure above 110 mmHg
             (after at least 3 min in supine position)

          -  Pregnant or breast-feeding woman and woman without adequate method of contraception.

          -  Known hypersensitivity to the active substance or to any of the excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klio Ai Becker, MD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Augenheilkunde, Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 21, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

